320 related articles for article (PubMed ID: 19013488)
1. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs.
Tan A; Simovic S; Davey AK; Rades T; Prestidge CA
J Control Release; 2009 Feb; 134(1):62-70. PubMed ID: 19013488
[TBL] [Abstract][Full Text] [Related]
2. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs.
Simovic S; Heard P; Hui H; Song Y; Peddie F; Davey AK; Lewis A; Rades T; Prestidge CA
Mol Pharm; 2009; 6(3):861-72. PubMed ID: 19358600
[TBL] [Abstract][Full Text] [Related]
3. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems.
Tan A; Simovic S; Davey AK; Rades T; Boyd BJ; Prestidge CA
Mol Pharm; 2010 Apr; 7(2):522-32. PubMed ID: 20063867
[TBL] [Abstract][Full Text] [Related]
4. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation.
Nguyen TH; Tan A; Santos L; Ngo D; Edwards GA; Porter CJ; Prestidge CA; Boyd BJ
J Control Release; 2013 Apr; 167(1):85-91. PubMed ID: 23353808
[TBL] [Abstract][Full Text] [Related]
5. An oral delivery system for indomethicin engineered from cationic lipid emulsions and silica nanoparticles.
Simovic S; Hui H; Song Y; Davey AK; Rades T; Prestidge CA
J Control Release; 2010 May; 143(3):367-73. PubMed ID: 20079390
[TBL] [Abstract][Full Text] [Related]
6. Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases.
Rao S; Richter K; Nguyen TH; Boyd BJ; Porter CJ; Tan A; Prestidge CA
Mol Pharm; 2015 Dec; 12(12):4424-33. PubMed ID: 26523928
[TBL] [Abstract][Full Text] [Related]
7. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib.
Tan A; Davey AK; Prestidge CA
Pharm Res; 2011 Sep; 28(9):2273-87. PubMed ID: 21560021
[TBL] [Abstract][Full Text] [Related]
8. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations.
Yasmin R; Tan A; Bremmell KE; Prestidge CA
J Pharm Sci; 2014 Sep; 103(9):2950-2959. PubMed ID: 24585389
[TBL] [Abstract][Full Text] [Related]
9. Silica-lipid hybrid microcapsules: influence of lipid and emulsifier type on in vitro performance.
Lim LH; Tan A; Simovic S; Prestidge CA
Int J Pharm; 2011 May; 409(1-2):297-306. PubMed ID: 21371543
[TBL] [Abstract][Full Text] [Related]
10. Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy.
Zhao P; Jiang H; Jiang T; Zhi Z; Wu C; Sun C; Zhang J; Wang S
Eur J Pharm Sci; 2012 Apr; 45(5):639-47. PubMed ID: 22251657
[TBL] [Abstract][Full Text] [Related]
11. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
[TBL] [Abstract][Full Text] [Related]
12. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Dening TJ; Rao S; Thomas N; Prestidge CA
Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
[TBL] [Abstract][Full Text] [Related]
13. Nanoemulsion: a promising tool for solubility and dissolution enhancement of celecoxib.
Shakeel F; Faisal MS
Pharm Dev Technol; 2010; 15(1):53-6. PubMed ID: 19552546
[TBL] [Abstract][Full Text] [Related]
14. Mesoporous carbon with spherical pores as a carrier for celecoxib with needle-like crystallinity: improve dissolution rate and bioavailability.
Zhu W; Zhao Q; Sun C; Zhang Z; Jiang T; Sun J; Li Y; Wang S
Mater Sci Eng C Mater Biol Appl; 2014 Jun; 39():13-20. PubMed ID: 24863191
[TBL] [Abstract][Full Text] [Related]
15. Supersaturated Silica-Lipid Hybrid Oral Drug Delivery Systems: Balancing Drug Loading and In Vivo Performance.
Schultz HB; Kovalainen M; Peressin KF; Thomas N; Prestidge CA
J Pharmacol Exp Ther; 2019 Sep; 370(3):742-750. PubMed ID: 30552294
[TBL] [Abstract][Full Text] [Related]
16. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
Li DX; Yan YD; Oh DH; Yang KY; Seo YG; Kim JO; Kim YI; Yong CS; Choi HG
Drug Deliv; 2010 Jul; 17(5):322-9. PubMed ID: 20367177
[TBL] [Abstract][Full Text] [Related]
17. Supersaturated silica-lipid hybrids (super-SLH): An improved solid-state lipid-based oral drug delivery system with enhanced drug loading.
Schultz HB; Thomas N; Rao S; Prestidge CA
Eur J Pharm Biopharm; 2018 Apr; 125():13-20. PubMed ID: 29277724
[TBL] [Abstract][Full Text] [Related]
18. Synergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin.
Rao S; Tan A; Boyd BJ; Prestidge CA
Nanomedicine (Lond); 2014 Dec; 9(18):2745-59. PubMed ID: 24938439
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs.
Hansen T; Holm P; Rohde M; Schultz K
Int J Pharm; 2005 Apr; 293(1-2):203-11. PubMed ID: 15778058
[TBL] [Abstract][Full Text] [Related]
20. Enhancing the oral bioavailability of simvastatin with silica-lipid hybrid particles: The effect of supersaturation and silica geometry.
Meola TR; Schultz HB; Peressin KF; Prestidge CA
Eur J Pharm Sci; 2020 Jul; 150():105357. PubMed ID: 32446169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
